Abstract
The humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a pivotal role in controlling coronavirus disease 2019 (COVID-19) infections. However, little is known about the persistence of the antibody response.
We evaluated that the kinetics of anti-nucleocapsid protein antibody of SARS-CoV2 infected healthcare workers in COVID-19 cluster occurred hospital. The long-term kinetics of anti-N antibody was classified high and keep pattern, high and decay pattern, and low and keep pattern. COVID-19 contact and symptomaticity was not related to kinetic patterns.
The reason of kinetic difference was still unclear. However natural anti-SARS-CoV-2 antibody persistence was not uniform, suggesting inter-individual difference of SARS-CoV2 vaccine efficacy.
Competing Interest Statement
SK and AO had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: AO and AK. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: SK, AO, and AK. Administrative, technical, or material support: SK, YK, MO, YY, TM.
Clinical Trial
Ethics approval: The study was approved by the local Ethics Committee of DOPH and registered in University Hospital Medical Information Network (UMIN) clinical trials registry in Japan (UMIN000040453).
Funding Statement
This work was supported by research grants from Japan Agency for Medical Research and Development (AMED) (grant no. 18059042 and JP19ek0109307, 200705710 and JP20fk0108265, 200705079 and JP20nk0101612 to AK); Center of Innovation stream and Sports Research Innovation Project grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (to AK); grants from MEXT/Japan Society for the Promotion of Science (JSPS) KAKENHI (grant no. JP18H05282 to AK).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local Ethics Committee of Daini Osaka Police Hospital ()
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of Interest AO; personal fees: Chugai, Eli Lilly, Asahi-Kasei Pharma, Daiichi Sankyo, Bristol-Myers Squibb, Janssen, Sanofi, GlaxoSmithKline, outside the submitted work. SK, YK, MO, YY, TM, and AK have nothing to disclose.
Contributors: SK and AO had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: AO and AK. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: SK, AO, and AK. Administrative, technical, or material support: SK, YK, MO, YY, TM.
Funding: This work was supported by research grants from Japan Agency for Medical Research and Development (AMED) (grant no. 18059042 and JP19ek0109307, 200705710 and JP20fk0108265, 200705079 and JP20nk0101612 to AK); Center of Innovation stream and Sports Research Innovation Project grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (to AK); grants from MEXT/Japan Society for the Promotion of Science (JSPS) KAKENHI (grant no. JP18H05282 to AK).
Ethics approval: The study was approved by the local Ethics Committee of DOPH and registered in University Hospital Medical Information Network (UMIN) clinical trials registry in Japan (UMIN000040453).
Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
